ArticleFrontiers in oncology2026
LF3 exerts anti-osteosarcoma effects through Wnt signaling inhibition-coupled ferroptosis induction via
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma, the most common primary malignant bone tumor, predominantly affects adolescents and is characterized by high aggressiveness and early metastatic propensity. Chemoresistance and recurrence remain major clinical challenges, highlighting the urgent need for novel therapeutic targets and molecular mechanisms. Methods: Bioinformatics analysis of the GEO dataset (GSE42352) revealed a negative correlation between Wnt target gene expression and ferroptosis‑related gene signatures. The expression of Wnt and ferroptosis pathway genes/proteins, as well as autophagy and pyroptosis markers, was validated in 143B and MG63 cells by qRT‑PCR and Western blotting. ROS, Fe Results: Bioinformatics analysis of the GEO dataset (GSE42352) revealed a negative correlation between Wnt target gene expression and ferroptosis‑related gene signatures, suggesting that ferroptosis may be involved. In 143B and MG‑63 cells, LF3 (40 μM) downregulated Wnt target genes (AXIN2, BMP4, SMAD6, LEF1) and TCF4 protein expression, significantly inhibiting cell proliferation, migration, and invasion. LF3 treatment induced ROS elevation, lipid peroxidation, and characteristic mitochondrial morphological changes, independent of apoptosis, autophagy, or pyroptosis. Mechanistic studies demonstrated that LF3 activated ferroptosis through upregulation of HO‑1 and ACSL4/LPCAT3. In an osteosarcoma xenograft model, LF3 reduced tumor volume by approximately 60%, accompanied by elevated serum ferritin and tumor 4‑HNE levels; these effects were partially reversed by DFO co‑treatment. No systemic toxicity was observed. Conclusion: These findings establish LF3 as a dual-targeting agent that overcomes osteosarcoma through coordinated Wnt suppression and ferroptosis activation via the HO-1/ACSL4 axis, providing a novel therapeutic strategy for chemoresistant osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.